DEA Delays Medical Marijuana Clinical Trials Yet Illicit Market Continues To Thrive

As states legalize marijuana, some as long as 10 years ago, many are beginning to realize the public health and safety implications of a variety of new high-potency products as questions about possible links to psychosis arise. 

MMJ BioPharma Labs is positioned to perform analytical requirements that the Federal government may impose on the industry, as it was recently awarded a DEA schedule 1 cannabis analytical lab license.

Some newer concentrates products, commonly known as wax and shatter, can have THC levels as high as 85 to 90 percent. By comparison, researchers say, THC levels of a typical joint 20 years ago were closer to 5 percent.

The FDA is now sending cease and desist letters to several companies.

At a January forum, the director of the National Institute on Drug Abuse, Dr. Nora Volkow raised concerns about the increasingly public consumption of high-potency cannabis

Volkow said she worries that "huge concentrations" of THC could have serious consequences. "We are seeing a very significant rise in psychosis associated with the consumption of marijuana. And the higher the content of THC, the higher the likelihood of a psychotic episode."

Duane Boise president and founder of MMJ stated "it remains an ongoing research question as to the results that we will find by conducting our FDA sanctioned clinical trials. Whether or not such psychotic episodes can lead to permanent schizophrenia or vomiting illness is yet to be determined."

MMJ is building a center of marijuana excellence in Rhode Island and has filed for FDA sanctioned clinical trials in multiple sclerosis and Huntington's disease. The company is awaiting the final DEA award to cultivate its strain-specific marijuana to supply the clinical trials. Meanwhile, the illicit market is thriving.

DEA DELAYS MMJ CLINICAL TRIALS from MMJ International Holding on Vimeo.

Related News

'DEA Has Blown It Again' - MMJ Request Federal Court Action For Emergency Motion To Expedite

MMJ BioPharma Cultivation To Produce Quality Cannabis, Meeting DEA's Definition Of Chemical Reproducibility

 

 

 

Posted In: DEADr. Nora VolkowDuane BoiseMMJ BioPharma LabsCannabisNewsFDAMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.